Identification

Name
Gabapentin
Accession Number
DB00996  (APRD00015)
Type
Small Molecule
Groups
Approved, Investigational
Description

Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain. Gabapentin is well tolerated in most patients, has a relatively mild side-effect profile, and passes through the body unmetabolized.

Structure
Thumb
Synonyms
  • 1-(Aminomethyl)cyclohexaneacetic acid
  • Gabapentin GR
  • Gabapentina
  • Gabapentine
  • Gabapentino
  • Gabapentinum
  • Gabapetin
External IDs
CI-945 / DM-1796 / GOE 3450 / GOE-3450
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act GabapentinCapsule400 mgOralActavis Pharma Company2005-02-16Not applicableCanada
Act GabapentinCapsule300 mgOralActavis Pharma Company2005-02-16Not applicableCanada
Act GabapentinCapsule100 mgOralActavis Pharma Company2005-02-16Not applicableCanada
Auro-gabapentinCapsule100 mgOralAuro Pharma Inc2011-06-15Not applicableCanada
Auro-gabapentinCapsule300 mgOralAuro Pharma Inc2011-06-15Not applicableCanada
Auro-gabapentinCapsule400 mgOralAuro Pharma Inc2011-06-15Not applicableCanada
Auro-gabapentin TabletsTablet800 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-gabapentin TabletsTablet600 mgOralAuro Pharma IncNot applicableNot applicableCanada
Bci GabapentinCapsule300 mgOralBaker Cummins IncNot applicableNot applicableCanada
Bio-gabapentinTablet800 mgOralBiomed PharmaNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-gabapentinTablet600 mgOralApotex Corporation2008-06-04Not applicableCanada
Apo-gabapentinTablet800 mgOralApotex Corporation2008-06-04Not applicableCanada
Apo-gabapentin CapsulesCapsule400 mgOralApotex Corporation2001-08-27Not applicableCanada
Apo-gabapentin CapsulesCapsule100 mgOralApotex Corporation2001-08-27Not applicableCanada
Apo-gabapentin CapsulesCapsule300 mgOralApotex Corporation2001-08-27Not applicableCanada
GabapentinCapsule400 mg/1OralUnit Dose Services2009-11-24Not applicableUs
GabapentinCapsule400 mg/1OralMethod Pharmaceuticals2016-09-30Not applicableUs
GabapentinCapsule100 mg/1OralCardinal Health2010-05-10Not applicableUs
GabapentinCapsule100 mg/1OralAphena Pharma Solutions Tennessee, Inc.2004-10-04Not applicableUs
GabapentinCapsule300 mg/1OralNucare Pharmaceuticals, Inc.2016-06-29Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FanatrexKitOralCalifornia Pharmaceuticals, Llc2010-05-15Not applicableUs
FanatrexKitOralCalifornia Pharmaceuticals, Llc2016-01-01Not applicableUs
GabapentinCapsule300 mg/1OralJiangsu Hengrui Medicine Co. Ltd.2017-10-26Not applicableUs
GabapentinCapsule300 mg/1OralPreferreed Pharmaceuticals Inc.2017-10-31Not applicableUs
GabapentinTablet, film coated800 mg/1OralRemedy Repack2017-10-30Not applicableUs
GabapentinCapsule400 mg/1OralJiangsu Hengrui Medicine Co. Ltd.2017-10-26Not applicableUs
GabapentinCapsule300 mg/1OralPreferreed Pharmaceuticals Inc.2017-10-31Not applicableUs
GabapentinCapsule100 mg/1OralJiangsu Hengrui Medicine Co. Ltd.2017-10-26Not applicableUs
GabapentinCapsule400 mg/1OralPreferreed Pharmaceuticals Inc.2017-10-30Not applicableUs
GabapentinTablet600 mg/1OralPreferreed Pharmaceuticals Inc.2017-10-31Not applicableUs
International/Other Brands
Aclonium / Neurontin / Novo-Gabapentin
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Dipentocaine Topical Cream Compounding KitGabapentin + Diclofenac sodium + Lidocaine hydrochlorideKitTopicalAlvix Laboratories2014-11-06Not applicableUs
Gapeam BudibacGabapentin + Amantadine hydrochloride + Baclofen + Bupivacaine hydrochloride + Cyclobenzaprine Hydrochloride + Diclofenac sodium + PentoxifyllineKitTopicalAlvix Laboratories2014-12-05Not applicableUs
SmartRx Gaba KitGabapentin + Lidocaine hydrochloride + MentholKitOral; TopicalMas Management Group Inc.2009-11-24Not applicableUs
SmartRx Gaba-V KitGabapentin + Capsaicin + Menthol + Methyl salicylateKitMas Management Group Inc2009-03-16Not applicableUs
Therapentin-60Gabapentin + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-05-172016-10-13Us
Therapentin-90Gabapentin + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-02-082016-10-13Us
Topical Nerve PainGabapentin (.1 g/100mL) + Diazepam (.1 g/100mL) + Diclofenac sodium (.1 g/100mL) + Ketamine (.1 g/100mL)CreamTopicalDr Marc's Manufacturing And Sales2016-02-23Not applicableUs
Categories
UNII
6CW7F3G59X
CAS number
60142-96-3
Weight
Average: 171.2368
Monoisotopic: 171.125928793
Chemical Formula
C9H17NO2
InChI Key
UGJMXCAKCUNAIE-UHFFFAOYSA-N
InChI
InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)
IUPAC Name
2-[1-(aminomethyl)cyclohexyl]acetic acid
SMILES
NCC1(CC(O)=O)CCCCC1

Pharmacology

Indication

For the management of postherpetic neuralgia in adults and as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy.

Structured Indications
Pharmacodynamics

Gabapentin, an analog of GABA, is used as an anticonvulsant to treat partial seizures, amyotrophic lateral sclerosis (ALS), and painful neuropathies. Potential uses include monotherapy of refractory partial seizure disorders, and treatment of spasticity in multiple sclerosis, tremor. mood disorders, and attenuation of disruptive behaviors in dementia. Gabapentin has high lipid solubility, is not metabolized by the liver, has no protein binding, and doesn't possess the usual drug interactions.

Mechanism of action

Gabapentin interacts with cortical neurons at auxillary subunits of voltage-sensitive calcium channels. Gabapentin increases the synaptic concentration of GABA, enhances GABA responses at non-synaptic sites in neuronal tissues, and reduces the release of mono-amine neurotransmitters. One of the mechanisms implicated in this effect of gabapentin is the reduction of the axon excitability measured as an amplitude change of the presynaptic fibre volley (FV) in the CA1 area of the hippocampus. This is mediated through its binding to presynaptic NMDA receptors. Other studies have shown that the antihyperalgesic and antiallodynic effects of gabapentin are mediated by the descending noradrenergic system, resulting in the activation of spinal alpha2-adrenergic receptors. Gabapentin has also been shown to bind and activate the adenosine A1 receptor.

TargetActionsOrganism
AVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-2
inhibitor
Human
AVoltage-dependent N-type calcium channel subunit alpha-1B
inhibitor
Human
UAdenosine receptor A1
agonist
Human
UNMDA receptorNot AvailableHuman
UGamma-aminobutyric acid type B receptor subunit 1Not AvailableHuman
UGamma-aminobutyric acid type B receptor subunit 2Not AvailableHuman
Absorption

Rapid. Absorbed in part by the L-amino acid transport system, which is a carrier-mediated, saturable transport system; as the dose increases, bioavailability decreases. Bioavailability ranges from approximately 60% for a 900 mg dose per day to approximately 27% for a 4800 milligram dose per day. Food has a slight effect on the rate and extent of absorption of gabapentin (14% increase in AUC).

Volume of distribution
  • 58±6 L
Protein binding

Less than 3% of gabapentin circulates bound to plasma protein.

Metabolism

All pharmacological actions following gabapentin administration are due to the activity of the parent compound; gabapentin is not appreciably metabolized in humans.

Route of elimination

Gabapentin is eliminated from the systemic circulation by renal excretion as unchanged drug. Gabapentin is not appreciably metabolized in humans.

Half life

5-7 hours

Clearance
  • 190 mL/min
Toxicity

Symptoms of overdose include ataxia, labored breathing, ptosis, sedation, hypoactivity, and excitation.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Gabapentin.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Gabapentin.Vet Approved
7-NitroindazoleThe risk or severity of adverse effects can be increased when Gabapentin is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Gabapentin is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Gabapentin.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Gabapentin.Approved, Investigational
AlgeldrateThe serum concentration of Gabapentin can be decreased when it is combined with Algeldrate.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Allopregnanolone.Investigational
AlmagateThe serum concentration of Gabapentin can be decreased when it is combined with Almagate.Experimental
AlmasilateThe serum concentration of Gabapentin can be decreased when it is combined with Almasilate.Experimental
AloglutamolThe serum concentration of Gabapentin can be decreased when it is combined with Aloglutamol.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Gabapentin.Approved, Illicit, Investigational
AluminiumThe serum concentration of Gabapentin can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Gabapentin can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Gabapentin can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Gabapentin can be decreased when it is combined with Aluminum hydroxide.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Gabapentin.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Gabapentin.Approved, Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Gabapentin.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Gabapentin is combined with Aripiprazole.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Gabapentin.Approved
ArticaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Asenapine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Atosiban.Approved
Atracurium besylateGabapentin may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Azaperone.Vet Approved
AzelastineGabapentin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Gabapentin is combined with Baclofen.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Gabapentin.Experimental
BarbexacloneThe metabolism of Gabapentin can be increased when combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Benzocaine.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Gabapentin.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Gabapentin is combined with Benzyl alcohol.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Gabapentin.Approved
Bismuth SubcitrateThe serum concentration of Gabapentin can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Gabapentin can be decreased when it is combined with Bismuth subnitrate.Experimental
Brefeldin AThe risk or severity of adverse effects can be increased when 1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE is combined with Gabapentin.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Gabapentin is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved
BromazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Brotizolam.Approved, Withdrawn
BucindololBucindolol may increase the hypotensive activities of Gabapentin.Investigational
BunazosinBunazosin may increase the hypotensive activities of Gabapentin.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bupivacaine.Approved, Investigational
BuprenorphineGabapentin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Gabapentin.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Gabapentin.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Gabapentin is combined with Butamben.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Gabapentin.Approved
ButethalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Butethal.Approved, Illicit
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Gabapentin.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Gabapentin.Approved, Illicit, Vet Approved
CalciumThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe serum concentration of Gabapentin can be decreased when it is combined with Calcium Carbonate.Approved
Calcium CitrateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium lactate.Approved, Experimental, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Phosphate.Approved
Calcium silicateThe serum concentration of Gabapentin can be decreased when it is combined with Calcium silicate.Experimental
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Gabapentin.Withdrawn
CanertinibThe risk or severity of adverse effects can be increased when Gabapentin is combined with Canertinib.Investigational
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Gabapentin.Experimental
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Gabapentin.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Carbinoxamine.Approved
CarbomycinThe metabolism of Gabapentin can be decreased when combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Gabapentin is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Carisoprodol.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Gabapentin.Approved, Investigational
CaseinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Gabapentin.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Gabapentin.Approved
CetirizineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Gabapentin.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chloroprocaine.Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Gabapentin.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Gabapentin.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorzoxazone.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Gabapentin.Approved, Investigational
CimetidineThe serum concentration of Gabapentin can be increased when it is combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Gabapentin is combined with Citalopram.Approved
ClarithromycinThe metabolism of Gabapentin can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Gabapentin is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Gabapentin.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Gabapentin.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clothiapine.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Gabapentin.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Gabapentin.Approved
CocaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Gabapentin.Approved, Illicit
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Gabapentin.Investigational
CyclizineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gabapentin.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Gabapentin.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dapiprazole.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Gabapentin.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Gabapentin.Approved, Illicit, Vet Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Gabapentin.Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Gabapentin is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Doramectin.Vet Approved
DoxazosinDoxazosin may increase the hypotensive activities of Gabapentin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Gabapentin is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ecgonine.Experimental, Illicit
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Gabapentin.Approved
EcopipamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Gabapentin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Gabapentin.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Gabapentin is combined with Entacapone.Approved, Investigational
ErythromycinThe metabolism of Gabapentin can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Gabapentin is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Gabapentin.Approved
EthanolGabapentin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Gabapentin.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Gabapentin.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluanisone.Experimental
FluconazoleThe serum concentration of Gabapentin can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Gabapentin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Gabapentin.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Gabapentin.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Gabapentin.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluticasone propionate.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Gabapentin.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Gabapentin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fospropofol.Approved, Illicit
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gabapentin is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Gabapentin is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Glutethimide.Approved, Illicit
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Gabapentin.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Gabapentin.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Guanfacine.Approved, Investigational
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Gabapentin.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Gabapentin.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Gabapentin.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Heroin.Approved, Illicit
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Gabapentin.Approved
HexobarbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Hexobarbital.Approved
HydrocodoneGabapentin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Gabapentin.Approved, Illicit
HydrotalciteThe serum concentration of Gabapentin can be decreased when it is combined with Hydrotalcite.Experimental
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Gabapentin is combined with Indiplon.Investigational
IndoraminIndoramin may increase the hypotensive activities of Gabapentin.Withdrawn
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Gabapentin.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Gabapentin.Approved, Vet Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Gabapentin.Approved, Investigational
JosamycinThe metabolism of Gabapentin can be decreased when combined with Josamycin.Approved
KetamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketobemidone.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Gabapentin.Approved, Investigational
KitasamycinThe metabolism of Gabapentin can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Gabapentin.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Gabapentin.Approved
LidocaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Gabapentin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lormetazepam.Approved
LovastatinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Gabapentin.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lurasidone.Approved
MagaldrateThe serum concentration of Gabapentin can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium HydroxideMagnesium Hydroxide may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved
Magnesium oxideMagnesium oxide may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved
Magnesium peroxideThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium salicylateMagnesium salicylate may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved
Magnesium silicateThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium silicate.Experimental
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Gabapentin is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Melperone.Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Gabapentin.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Gabapentin.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Gabapentin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Gabapentin.Approved
MethotrimeprazineGabapentin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methylphenobarbital.Approved
MetyrosineGabapentin may increase the sedative activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Gabapentin.Experimental
MianserinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Mianserin.Approved
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Gabapentin.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Gabapentin.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Gabapentin.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Gabapentin is combined with Milnacipran.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Gabapentin.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
MirtazapineGabapentin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumGabapentin may increase the neuromuscular blocking activities of Mivacurium.Approved
MolindoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Molindone.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Gabapentin.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Gabapentin.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Gabapentin.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
NafcillinThe metabolism of Gabapentin can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Gabapentin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Gabapentin.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Gabapentin.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nefazodone.Approved, Withdrawn
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Gabapentin.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Gabapentin.Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nitrazepam.Approved
NitroprussideGabapentin may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nitrous oxide.Approved, Vet Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Gabapentin.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nortriptyline.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Gabapentin.Approved, Vet Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Gabapentin.Approved, Investigational
OleandomycinThe metabolism of Gabapentin can be decreased when combined with Oleandomycin.Vet Approved
OlopatadineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Olopatadine.Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Gabapentin.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Gabapentin is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Gabapentin can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineGabapentin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Gabapentin is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Gabapentin.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxethazaine.Investigational
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Gabapentin.Approved
OxprenololThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gabapentin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxymorphone.Approved, Investigational, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Gabapentin.Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paliperidone.Approved
ParaldehydeGabapentin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Penfluridol.Experimental
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Gabapentin.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Gabapentin.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Gabapentin.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved
PerazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Gabapentin is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Gabapentin.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Gabapentin.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Gabapentin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Piritramide.Investigational
PitavastatinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pitavastatin.Approved
PizotifenThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pomalidomide.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Gabapentin.Approved, Investigational, Vet Approved
PramipexoleGabapentin may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pramocaine.Approved
PravastatinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the hypotensive activities of Gabapentin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Gabapentin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gabapentin.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Gabapentin.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Gabapentin is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Gabapentin.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Gabapentin is combined with PSD502.Investigational
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Gabapentin.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Quetiapine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Raclopride.Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Gabapentin.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ramelteon.Approved, Investigational
RapacuroniumGabapentin may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Gabapentin.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Gabapentin.Approved
RifabutinThe serum concentration of Gabapentin can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Gabapentin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Gabapentin can be decreased when it is combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Gabapentin.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Romifidine.Vet Approved
RopiniroleGabapentin may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ropivacaine.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Rosuvastatin.Approved
RotigotineGabapentin may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Gabapentin.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Gabapentin.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Gabapentin.Approved, Vet Approved
ScopolamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Gabapentin.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sepranolone.Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Gabapentin.Approved
SertindoleThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sevoflurane.Approved, Vet Approved
SilodosinSilodosin may increase the hypotensive activities of Gabapentin.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Gabapentin.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Gabapentin.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved
SolithromycinThe metabolism of Gabapentin can be decreased when combined with Solithromycin.Investigational
StiripentolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Gabapentin.Approved
SulpirideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sultopride.Experimental
SuvorexantGabapentin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Gabapentin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tasimelteon.Approved
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Gabapentin.Approved
TelithromycinThe metabolism of Gabapentin can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Gabapentin.Approved
TerazosinTerazosin may increase the hypotensive activities of Gabapentin.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Gabapentin.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Gabapentin.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrodotoxin.Investigational
ThalidomideGabapentin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Gabapentin.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiothixene.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Gabapentin.Approved
TiagabineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tilidine.Experimental
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Gabapentin.Approved
TizanidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tolcapone.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Gabapentin.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Gabapentin.Approved, Vet Approved
TopiramateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Gabapentin.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Gabapentin.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gabapentin.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Gabapentin.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Gabapentin.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Triprolidine.Approved
TylosinThe metabolism of Gabapentin can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ubidecarenone.Experimental
UrapidilUrapidil may increase the hypotensive activities of Gabapentin.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Gabapentin is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vinyl ether.Experimental
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Gabapentin.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Gabapentin is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Gabapentin.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Gabapentin.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zolazepam.Vet Approved
ZolpidemGabapentin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference

Donald E. Butler, Barbara J. Greenman, "Gabapentin mohohydrate and a process for producing the same." U.S. Patent US4960931, issued May, 1978.

US4960931
General References
  1. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S: Efficacy of gabapentin in migraine prophylaxis. Headache. 2001 Feb;41(2):119-28. [PubMed:11251695]
  2. Backonja MM, Serra J: Pharmacologic management part 1: better-studied neuropathic pain diseases. Pain Med. 2004 Mar;5 Suppl 1:S28-47. [PubMed:14996228]
  3. Choudhuri I, Sarvananthan N, Gottlob I: Survey of management of acquired nystagmus in the United Kingdom. Eye (Lond). 2007 Sep;21(9):1194-7. Epub 2006 May 26. [PubMed:16732211]
  4. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G: Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2000 Sep;2(3 Pt 2):249-55. [PubMed:11249802]
  5. Su TZ, Feng MR, Weber ML: Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther. 2005 Jun;313(3):1406-15. Epub 2005 Mar 15. [PubMed:15769862]
External Links
Human Metabolome Database
HMDB05015
KEGG Drug
D00332
PubChem Compound
3446
PubChem Substance
46506529
ChemSpider
3328
BindingDB
50080153
ChEBI
42797
ChEMBL
CHEMBL940
Therapeutic Targets Database
DNC000670
PharmGKB
PA449720
HET
GBN
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Gabapentin
ATC Codes
N03AX12 — Gabapentin
AHFS Codes
  • 28:12.92 — Miscellaneous Anticonvulsants
PDB Entries
2a1h / 2coi / 2coj / 2ej3
FDA label
Download (1.5 MB)
MSDS
Download (73.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentLumbar Spinal Instability / Lumbar Spine Degeneration / Spinal Stenosis of Lumbar Region1
0RecruitingTreatmentPain, Acute1
0WithdrawnTreatmentTourniquet-induced Hypertension / Tourniquet-induced Pain1
1CompletedNot AvailableDrug Dependence1
1CompletedNot AvailableHealthy Volunteers7
1CompletedOtherEpilepsies1
1CompletedPreventionPreterm Labor, Premature Birth1
1CompletedTreatmentDrug Usage1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentSleeplessness1
1WithdrawnTreatmentPruritus1
1, 2CompletedPreventionFeeling Anxious / Pain1
1, 2RecruitingNot AvailableClinical High Risk for Psychosis1
2Active Not RecruitingTreatmentIrritability / Neurologically Impaired / Pain, Chronic / Signs and Symptoms, Digestive / Sleeplessness1
2Active Not RecruitingTreatmentMenopausal Hot Flushes1
2CompletedSupportive CareMucositis1
2CompletedTreatmentAlcohol Dependence / Alcoholism1
2CompletedTreatmentAlcohol Withdrawal Syndrome(AWS)1
2CompletedTreatmentAlcoholism1
2CompletedTreatmentBenzodiazepine Dependence / Opioid Dependence1
2CompletedTreatmentCannabis Dependence1
2CompletedTreatmentCannabis Dependence / Cannabis Withdrawal / Cognitive Deficits1
2CompletedTreatmentChronic Low Back Pain (CLBP)1
2CompletedTreatmentDependence, Cocaine / Depressive Symptoms1
2CompletedTreatmentDiabetic Peripheral Neuropathy (DPN)1
2CompletedTreatmentMenopausal Hot Flushes1
2CompletedTreatmentNerve Pain / Neuropathy / Post-Herpetic Neuralgia (PHN)1
2CompletedTreatmentOpiate withdrawal symptoms / Opioid Dependence / Opioid Detoxification1
2CompletedTreatmentOpioid-Induced Hyperalgesia1
2CompletedTreatmentPendular Nystagmus Patients With Multiple Sclerosis1
2CompletedTreatmentPost-traumatic Neuropathic Pain1
2CompletedTreatmentPostoperative Complications1
2CompletedTreatmentSleep Initiation and Maintenance Disorders1
2CompletedTreatmentSmoking, Cigarette / Tobacco Use1
2CompletedTreatmentTinnitus1
2Not Yet RecruitingBasic ScienceAlcohol Use Disorder (AUD) / Opioid-use Disorder1
2Not Yet RecruitingTreatmentPain, Chronic1
2RecruitingBasic ScienceAlcohol Use Disorder (AUD) / Bipolar Disorder (BD)1
2RecruitingSupportive CareAcute Lymphoblastic Leukaemias (ALL) / Neuropathy / Pain, Neuropathic1
2RecruitingSupportive CareCancer of Breast / Cancer, Breast / Malignant Neoplasm of Female Breast1
2RecruitingTreatmentAlcohol Use Disorder (AUD) / Alcohol Withdrawal Syndrome(AWS)1
2RecruitingTreatmentOther Abortion / Spontaneous Abortions1
2RecruitingTreatmentSickle Cell Disorders1
2TerminatedTreatmentProstate Cancer1
2Unknown StatusTreatmentBenzodiazepine Dependence1
2Unknown StatusTreatmentIntervertebral Disc Displacement / Intervertebral Disc Herniation1
2Unknown StatusTreatmentTinnitus, Subjective1
2WithdrawnTreatmentFabry's Disease / Pain, Neuropathic1
2, 3CompletedPreventionProphylaxis against postoperative nausea and vomiting1
2, 3CompletedTreatmentAlcohol Dependence2
2, 3CompletedTreatmentDetrusor Uninhibited Activity / Incontinence / Nocturia / Quality of Life / Urinary Frequency / Urination urgency of1
2, 3CompletedTreatmentFemale Genital Diseases1
2, 3CompletedTreatmentFibromyalgia1
2, 3RecruitingPreventionEffect of Laryngoscopy and Tracheal Intubation1
2, 3RecruitingSupportive CareBladder Carcinoma1
2, 3RecruitingTreatmentDrug Dependence1
2, 3TerminatedTreatmentAnalgesia / Inguinal Hernias / Pain1
2, 3TerminatedTreatmentTinnitus1
3Active Not RecruitingSupportive CareCancer, Breast / Lung Cancers / Pain1
3Active Not RecruitingTreatmentPain1
3Active Not RecruitingTreatmentPain / Quality of Life1
3CompletedNot AvailableSeizures1
3CompletedPreventionPostoperative pain1
3CompletedSupportive CareCancer, Breast / Menopausal Hot Flushes2
3CompletedSupportive CareIntervertebral Disc Herniation1
3CompletedSupportive CareMenopausal Hot Flushes / Prostate Cancer1
3CompletedSupportive CareNausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedSupportive CareNeurotoxicity / Pain1
3CompletedTreatmentCarpal Tunnel Syndrome (CTS)2
3CompletedTreatmentCholestasis / Itching / Liver Cirrhosis / Liver Diseases / Pruritus1
3CompletedTreatmentCisplatin Adverse Reaction / Vomiting1
3CompletedTreatmentDiabetic Neuropathies / Polyneuropathies1
3CompletedTreatmentEpilepsy, Localization Related2
3CompletedTreatmentFibromyalgia1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentMenopausal Hot Flushes3
3CompletedTreatmentMenopausal Hot Flushes / Menopause1
3CompletedTreatmentPost-Operative Pain1
3CompletedTreatmentPostherpetic Neuralgia1
3CompletedTreatmentPostoperative pain1
3CompletedTreatmentScoliosis1
3CompletedTreatmentTransient Insomnia7
3Not Yet RecruitingPreventionAdjunct to general anesthesia therapy / Anaesthesia therapy / Analgesics / Analgesics, Opioid / Dexmedetomidine / Gabapentin / Ketamine / Lidocaine / Narcotics / Obstructive Sleep Apnea of Child / Oximetry, Pulse / Pathologic Processes / Physiologic Effects of Drugs / Postoperative Complications / Respiratory Depression / Sleep Disordered Breathing (SDB) / Tonsillectomy1
3Not Yet RecruitingPreventionHerpetic Neuralgia1
3Not Yet RecruitingTreatmentLiver Cirrhosis1
3RecruitingSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3RecruitingSupportive CareOropharynx Cancers1
3RecruitingTreatmentHyperemesis Gravidarum1
3RecruitingTreatmentPain, Chronic1
3RecruitingTreatmentPain, Chronic / Postoperative pain1
3RecruitingTreatmentPelvic Organ Prolapse (POP)1
3RecruitingTreatmentPelvic Pain1
3TerminatedNot AvailableNeuroleptic-Induced Tremor1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentFunctional Dyspepsia1
3WithdrawnPreventionPost-thoracotomy Pain1
4Active Not RecruitingTreatmentPeripheral Nerve Disorder Associated With Repair of Hernia1
4CompletedNot AvailableEpilepsy, Localization Related1
4CompletedBasic ScienceSleeplessness1
4CompletedBasic ScienceSynovitis of osteoarthritis1
4CompletedOtherHealthy Volunteers1
4CompletedPreventionProphylaxis against postoperative nausea and vomiting1
4CompletedSupportive CarePain1
4CompletedSupportive CarePain After Photorefractive Keratectomy1
4CompletedTreatmentAlcohol Withdrawal Syndrome(AWS)1
4CompletedTreatmentAmputation of Lower Limb1
4CompletedTreatmentAnalgesia / Postoperative pain1
4CompletedTreatmentAneurysmal Subarachnoid Hemorrhage1
4CompletedTreatmentBronchial Asthma1
4CompletedTreatmentCardiopulmonary Bypass1
4CompletedTreatmentCarpal Tunnel Syndrome (CTS) / Complex Regional Pain Syndrome (CRPS) / Diabetic Neuropathies / HIV Neuropathy / Idiopathic Sensory Neuropathy / Peripheral Neuropathy / Postherpetic Neuralgia1
4CompletedTreatmentColorectal Disorders1
4CompletedTreatmentComplex Partial Seizure Disorder / Epilepsies / Epilepsy, Localization Related / Partial Seizure Disorder1
4CompletedTreatmentDiabetic Neuropathies2
4CompletedTreatmentDiabetic Neuropathy, Painful1
4CompletedTreatmentDiabetic Peripheral Neuropathic Pain1
4CompletedTreatmentEpilepsy, Localization Related1
4CompletedTreatmentLaparoscopic Cholecystectomy / Postoperative pain1
4CompletedTreatmentMenopausal Hot Flushes1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentNeuropathy / Pain1
4CompletedTreatmentOculopalatal Tremor / Pendular Nystagmus1
4CompletedTreatmentOrthopedic Disorders / Postoperative pain1
4CompletedTreatmentParesthesia / Thoracic Pain1
4CompletedTreatmentPostoperative pain / Postoperative Sedation1
4CompletedTreatmentPostoperative pain2
4CompletedTreatmentProstate Cancer1
4Enrolling by InvitationPreventionPostoperative pain1
4Enrolling by InvitationTreatmentDiabetic Neuropathy, Painful / Pain, Neuropathic / Type 2 Diabetes Mellitus1
4Not Yet RecruitingPreventionAnaesthesia therapy / Urethral Obstruction1
4Not Yet RecruitingTreatmentFacial Pain / Pain, Acute / Postoperative pain1
4Not Yet RecruitingTreatmentPostoperative pain2
4RecruitingPreventionPelvic Organ Prolapse (POP)1
4RecruitingPreventionPostoperative pain1
4RecruitingSupportive CareColon Diverticulosis / Colonic Neoplasms / Constipation Drug Induced / Diverticulitis, Colonic / Ileus / Ileus paralytic / Ileus; Mechanical / Malignant Neoplasm of Colon / Occasional Constipation / Postoperative pain / Rectum Cancer / Rectum Neoplasm1
4RecruitingTreatmentAlcohol Dependence1
4RecruitingTreatmentAlcohol Withdrawal Syndrome(AWS)1
4RecruitingTreatmentCervical Preparation / Pain / Pregnancy Termination1
4RecruitingTreatmentEpilepsies / Pain, Chronic1
4RecruitingTreatmentHead and Neck Carcinoma / Pain, Acute / Postoperative pain1
4RecruitingTreatmentHerpes Zoster / Pain / Postherpetic Neuralgia1
4RecruitingTreatmentKnee Replacement Surgery / Pain1
4RecruitingTreatmentMyofacial Pain1
4RecruitingTreatmentPain2
4RecruitingTreatmentPain Management1
4RecruitingTreatmentPost-laminectomy Pain Syndrome1
4RecruitingTreatmentPostoperative pain1
4TerminatedTreatmentAbdominal Pain (AP) / Surgical Adhesions1
4TerminatedTreatmentChronic Low Back Pain (CLBP) / Diabetic Neuropathic Pain1
4TerminatedTreatmentChronic Neuropathic Pain1
4TerminatedTreatmentDegenerative Joint Disease of Hip and Knee1
4TerminatedTreatmentImpaired Renal Function1
4TerminatedTreatmentInterstitial Cystitis / Irritable Bowel Syndrome (IBS) / Pelvic Pain / Prostatitis / Ulcerative Colitis (UC)1
4TerminatedTreatmentPK Properties Of Gabapentin In Subjects With Impaired Renal Function1
4TerminatedTreatmentPain1
4TerminatedTreatmentPostoperative pain1
4TerminatedTreatmentRestless Legs Syndrome (RLS)1
4TerminatedTreatmentSleep1
4Unknown StatusTreatmentCholecystolithiasis1
4Unknown StatusTreatmentHyperalgesia1
4Unknown StatusTreatmentPlanned Abdominal Hysterectomy1
4WithdrawnPreventionKnee Arthroscopy / Shoulder Arthroscopy1
4WithdrawnTreatmentPost Operative Pain Control1
Not AvailableActive Not RecruitingNot AvailableCancer, Breast / Depressive State / Menopausal Hot Flushes / Psychosocial Effects of Cancer and Its Treatment1
Not AvailableActive Not RecruitingSupportive CareHead and Neck Squamous Cell Carcinoma (HNSCC) / Pain / Vesicular Stomatitis1
Not AvailableCompletedNot AvailableEpilepsy, Localization Related1
Not AvailableCompletedNot AvailableHealthy Volunteers4
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedOtherAlcohol Dependence / Sleeplessness1
Not AvailableCompletedPreventionPruritus1
Not AvailableCompletedSupportive CareAnxiety Disorders / Cancer, Breast / Depressive State / Menopausal Hot Flushes1
Not AvailableCompletedSupportive CareTotal Knee Arthroplasty (TKA)1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD) / Dementias1
Not AvailableCompletedTreatmentBurn Injuries / Pain1
Not AvailableCompletedTreatmentCerebral Tumors1
Not AvailableCompletedTreatmentChronic Pelvic Pain1
Not AvailableCompletedTreatmentFibromyalgia1
Not AvailableCompletedTreatmentHerpes Zoster / Post-Herpetic Neuralgia (PHN)1
Not AvailableCompletedTreatmentHyperalgesia / Opioid-Related Disorders1
Not AvailableCompletedTreatmentKnee Replacement Surgery / Post Operative Pain1
Not AvailableCompletedTreatmentMenopausal Hot Flushes / Menopause / Vasomotor Disturbance1
Not AvailableCompletedTreatmentNystagmus / Nystagmus, Pathological1
Not AvailableCompletedTreatmentPain4
Not AvailableCompletedTreatmentPost Operative Pain Management in Children With Tonsillectomy/Adenoidectomy1
Not AvailableCompletedTreatmentPostoperative pain3
Not AvailableCompletedTreatmentPostoperative pain / Total Hip Replacement1
Not AvailableCompletedTreatmentRadicular syndrome / Sciatica1
Not AvailableCompletedTreatmentSedation, Conscious1
Not AvailableCompletedTreatmentSleep Bruxism1
Not AvailableCompletedTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableCompletedTreatmentVulvodynia1
Not AvailableEnrolling by InvitationNot AvailableArthritis / Gout Acute / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis1
Not AvailableNot Yet RecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableNot Yet RecruitingTreatmentHerpes Zoster / Post-Herpetic Neuralgia (PHN)1
Not AvailableRecruitingTreatmentAmputations / Phantom Pain Following Amputation of Lower Limb1
Not AvailableRecruitingTreatmentAnal Condyloma / Fissure in Ano / Hemorrhoids / Rectal Fistulas1
Not AvailableTerminatedTreatmentComplex Regional Pain Syndrome I (CRPS I)1
Not AvailableTerminatedTreatmentPain1
Not AvailableTerminatedTreatmentPostoperative pain1
Not AvailableTerminatedTreatmentVulvar Pain Symptoms / Vulvar Vestibulitis Syndrome (Chronic Vulvar Pain Localized to the Vaginal Opening) / Vulvodynia (Chronic Vulvar Pain)1
Not AvailableUnknown StatusTreatmentObesity, Morbid / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
Not AvailableUnknown StatusTreatmentPediatric Chronic Neuropathic Pain1
Not AvailableUnknown StatusTreatmentPruritus / Uremia1
Not AvailableWithdrawnNot AvailablePain1
Not AvailableWithdrawnTreatmentCardiovascular Health / Vasomotor Symptoms1

Pharmacoeconomics

Manufacturers
  • Actavis elizabeth llc
  • Amneal pharmaceuticals ny llc
  • Apotex inc etobicoke site
  • Aurobindo pharma usa inc
  • Hikma pharmaceuticals
  • Invagen pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Pfizer pharmaceuticals ltd
  • Parke davis div warner lambert co
  • Glenmark generics ltd
  • Matrix laboratories ltd
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
KitOral
CapsuleOral100 mg/1
CapsuleOral100 mg/100mg
CapsuleOral300 mg/300mg
CapsuleOral300 mg/1
CapsuleOral400 mg/400mg
CapsuleOral400 mg/1
CapsuleOral600 mg/1
SolutionOral250 mg/5mL
SuspensionOral250 mg/5mL
TabletOral600 mg/1
TabletOral600 mg/600mg
TabletOral800 mg/800mg
TabletOral800 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral600 mg/1001
Tablet, film coatedOral600 mg/1
Tablet, film coatedOral800 mg/1
Kit
Tablet, multilayer, extended releaseOral600 mg
Tablet, multilayer, extended releaseOral800 mg
KitTopical
TabletOral600 mg
TabletOral800 mg
CapsuleOral100 mg
CapsuleOral300 mg
CapsuleOral400 mg
KitOral; Topical
Kit
CreamTopical
Prices
Unit descriptionCostUnit
Gabapentin powder30.0USD g
Neurontin 800 mg tablet4.73USD tablet
Neurontin 600 mg tablet3.94USD tablet
Gabapentin 800 mg tablet3.09USD tablet
Gabapentin 600 mg tablet2.58USD tablet
Neurontin 400 mg Capsule1.97USD capsule
Neurontin 300 mg Capsule1.67USD capsule
Gabapentin 400 mg tablet1.59USD tablet
Gabapentin 300 mg tablet1.32USD tablet
Gabapentin 400 mg Capsule1.21USD capsule
Gabapentin 300 mg Capsule1.02USD capsule
Apo-Gabapentin 400 mg Capsule0.76USD capsule
Co Gabapentin 400 mg Capsule0.76USD capsule
Mylan-Gabapentin 400 mg Capsule0.76USD capsule
Novo-Gabapentin 400 mg Capsule0.76USD capsule
Phl-Gabapentin 400 mg Capsule0.76USD capsule
Pms-Gabapentin 400 mg Capsule0.76USD capsule
Ran-Gabapentin 400 mg Capsule0.76USD capsule
Ratio-Gabapentin 400 mg Capsule0.76USD capsule
Neurontin 100 mg Capsule0.65USD capsule
Apo-Gabapentin 300 mg Capsule0.64USD capsule
Co Gabapentin 300 mg Capsule0.64USD capsule
Mylan-Gabapentin 300 mg Capsule0.64USD capsule
Novo-Gabapentin 300 mg Capsule0.64USD capsule
Phl-Gabapentin 300 mg Capsule0.64USD capsule
Pms-Gabapentin 300 mg Capsule0.64USD capsule
Ran-Gabapentin 300 mg Capsule0.64USD capsule
Ratio-Gabapentin 300 mg Capsule0.64USD capsule
Gabapentin 100 mg tablet0.53USD tablet
Gabapentin 100 mg Capsule0.41USD capsule
Neurontin 250 mg/5ml Solution0.32USD ml
Apo-Gabapentin 100 mg Capsule0.26USD capsule
Co Gabapentin 100 mg Capsule0.26USD capsule
Mylan-Gabapentin 100 mg Capsule0.26USD capsule
Novo-Gabapentin 100 mg Capsule0.26USD capsule
Phl-Gabapentin 100 mg Capsule0.26USD capsule
Pms-Gabapentin 100 mg Capsule0.26USD capsule
Ran-Gabapentin 100 mg Capsule0.26USD capsule
Ratio-Gabapentin 100 mg Capsule0.26USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2327285No2005-06-142019-05-10Canada
CA2215923No2001-10-092016-04-26Canada
US6054482Yes1997-10-252017-10-25Us
US7256216Yes2002-11-282022-11-28Us
US6340475No1996-09-192016-09-19Us
US6635280No1996-09-192016-09-19Us
US6488962No2000-06-202020-06-20Us
US6723340No2001-10-252021-10-25Us
US7438927No2004-02-262024-02-26Us
US8192756No2002-10-252022-10-25Us
US8252332No2002-10-252022-10-25Us
US8333992No2002-10-252022-10-25Us
US7731989No2002-10-252022-10-25Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)162-166 °CNot Available
water solubility4490 mg/LNot Available
logP-1.10SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility4.34 mg/mLALOGPS
logP-1.9ALOGPS
logP-1.3ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)4.63ChemAxon
pKa (Strongest Basic)9.91ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.32 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity46.33 m3·mol-1ChemAxon
Polarizability18.92 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.941
Blood Brain Barrier+0.9382
Caco-2 permeable-0.7271
P-glycoprotein substrateNon-substrate0.6557
P-glycoprotein inhibitor INon-inhibitor0.9789
P-glycoprotein inhibitor IINon-inhibitor0.8866
Renal organic cation transporterNon-inhibitor0.7982
CYP450 2C9 substrateNon-substrate0.893
CYP450 2D6 substrateNon-substrate0.8124
CYP450 3A4 substrateNon-substrate0.7612
CYP450 1A2 substrateNon-inhibitor0.9409
CYP450 2C9 inhibitorNon-inhibitor0.9273
CYP450 2D6 inhibitorNon-inhibitor0.9418
CYP450 2C19 inhibitorNon-inhibitor0.9547
CYP450 3A4 inhibitorNon-inhibitor0.8438
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9706
Ames testNon AMES toxic0.9162
CarcinogenicityNon-carcinogens0.8536
BiodegradationNot ready biodegradable0.7046
Rat acute toxicity1.6472 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9406
hERG inhibition (predictor II)Non-inhibitor0.8659
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-00di-0900000000-bccc9bd5f1637db7b6c7
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-00di-0900000000-67139ca9559173bf9859
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0006-9000000000-bfe6527f738e4c67eb2b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0900000000-bb175ef297a289e1936b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udr-0900000000-258d4493623d0ab7b415
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0f79-0900000000-bc24764f394c6fee34fd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-006ecd4a58af763b087f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-012c52738f11970adb8d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-8f0d390195aa406adb5d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uk9-0900000000-72f8d5cb88eda76dab56
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-3900000000-b634b4e7144ec6ffdc83
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ktn-9800000000-20c4131179b228ab3440
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00ke-9300000000-dd9d44ed4f16961ed075
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-f9a7deaa778e9d893ee8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-4f85e6ac9fd91a3e3b81
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uk9-0900000000-d3a4c5658e343cf3cf8d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-3900000000-712133d5b9eae1b27ffb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ktn-9800000000-c652847259e0851b428e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00ke-9200000000-77e258cf26b045a7e46e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-bb0075e8b8166387ff3a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0uk9-0900000000-9e92acbd730e00943058
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0pvs-9800000000-ba043efa192e3c526cab
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0aou-9000000000-f44876af37d1698389cd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-1900000000-8304d09827a02dd8f392
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0005-9800000000-aa9f205e389c72aead8d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-eb3bc990b07a9471ea6e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-6514211d36ec828dafb5
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0fk9-0900000000-fb527245013f4d56589f
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Gamma amino acids and derivatives
Alternative Parents
Amino fatty acids / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Gamma amino acid or derivatives / Amino fatty acid / Fatty acyl / Amino acid / Carboxylic acid / Monocarboxylic acid or derivatives / Organopnictogen compound / Primary amine / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
gamma-amino acid (CHEBI:42797)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Maneuf YP, Luo ZD, Lee K: alpha2delta and the mechanism of action of gabapentin in the treatment of pain. Semin Cell Dev Biol. 2006 Oct;17(5):565-70. Epub 2006 Sep 24. [PubMed:17067834]
  2. Hota D, Bansal V, Pattanaik S: Evaluation of ketamine, nimodipine, gabapentin and imipramine in partial sciatic nerve transection model of neuropathic pain in rat: an experimental study. Methods Find Exp Clin Pharmacol. 2007 Sep;29(7):443-6. [PubMed:17982508]
  3. Gazulla J, Tintore MA: The P/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: gabapentin and pregabalin may be of therapeutic benefit. Med Hypotheses. 2007;68(1):131-6. Epub 2006 Aug 8. [PubMed:16899342]
  4. Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J, Wratten J, Davies A, Dolphin AC: Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3628-33. doi: 10.1073/pnas.0708930105. Epub 2008 Feb 25. [PubMed:18299583]
  5. Hoffmann U, Dilekoz E, Kudo C, Ayata C: Gabapentin suppresses cortical spreading depression susceptibility. J Cereb Blood Flow Metab. 2010 Sep;30(9):1588-92. doi: 10.1038/jcbfm.2010.92. Epub 2010 Jun 30. [PubMed:20588320]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D2
Uniprot ID
Q9NY47
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight
129816.095 Da
References
  1. Hota D, Bansal V, Pattanaik S: Evaluation of ketamine, nimodipine, gabapentin and imipramine in partial sciatic nerve transection model of neuropathic pain in rat: an experimental study. Methods Find Exp Clin Pharmacol. 2007 Sep;29(7):443-6. [PubMed:17982508]
  2. Gazulla J, Tintore MA: The P/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: gabapentin and pregabalin may be of therapeutic benefit. Med Hypotheses. 2007;68(1):131-6. Epub 2006 Aug 8. [PubMed:16899342]
  3. Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J, Wratten J, Davies A, Dolphin AC: Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3628-33. doi: 10.1073/pnas.0708930105. Epub 2008 Feb 25. [PubMed:18299583]
  4. Hoffmann U, Dilekoz E, Kudo C, Ayata C: Gabapentin suppresses cortical spreading depression susceptibility. J Cereb Blood Flow Metab. 2010 Sep;30(9):1588-92. doi: 10.1038/jcbfm.2010.92. Epub 2010 Jun 30. [PubMed:20588320]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1B
Uniprot ID
Q00975
Uniprot Name
Voltage-dependent N-type calcium channel subunit alpha-1B
Molecular Weight
262493.84 Da
References
  1. Cheng JK, Chen CC, Yang JR, Chiou LC: The antiallodynic action target of intrathecal gabapentin: Ca2+ channels, KATP channels or N-methyl-d-aspartic acid receptors? Anesth Analg. 2006 Jan;102(1):182-7. [PubMed:16368827]
  2. Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J, Wratten J, Davies A, Dolphin AC: Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3628-33. doi: 10.1073/pnas.0708930105. Epub 2008 Feb 25. [PubMed:18299583]
  3. Hoffmann U, Dilekoz E, Kudo C, Ayata C: Gabapentin suppresses cortical spreading depression susceptibility. J Cereb Blood Flow Metab. 2010 Sep;30(9):1588-92. doi: 10.1038/jcbfm.2010.92. Epub 2010 Jun 30. [PubMed:20588320]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Purine nucleoside binding
Specific Function
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
ADORA1
Uniprot ID
P30542
Uniprot Name
Adenosine receptor A1
Molecular Weight
36511.325 Da
References
  1. De Vry J, Kuhl E, Franken-Kunkel P, Eckel G: Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur J Pharmacol. 2004 May 3;491(2-3):137-48. [PubMed:15140630]
  2. Zuchora B, Wielosz M, Urbanska EM: Adenosine A1 receptors and the anticonvulsant potential of drugs effective in the model of 3-nitropropionic acid-induced seizures in mice. Eur Neuropsychopharmacol. 2005 Jan;15(1):85-93. [PubMed:15572277]
  3. Kralic JE, Criswell HE, Osterman JL, O'Buckley TK, Wilkie ME, Matthews DB, Hamre K, Breese GR, Homanics GE, Morrow AL: Genetic essential tremor in gamma-aminobutyric acidA receptor alpha1 subunit knockout mice. J Clin Invest. 2005 Mar;115(3):774-9. [PubMed:15765150]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated cation channel activity
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic p...

Components:
References
  1. Shimoyama M, Shimoyama N, Hori Y: Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain. 2000 Apr;85(3):405-14. [PubMed:10781913]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
G-protein coupled gaba receptor activity
Specific Function
Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2. Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coup...
Gene Name
GABBR1
Uniprot ID
Q9UBS5
Uniprot Name
Gamma-aminobutyric acid type B receptor subunit 1
Molecular Weight
108319.4 Da
References
  1. Ng GY, Bertrand S, Sullivan R, Ethier N, Wang J, Yergey J, Belley M, Trimble L, Bateman K, Alder L, Smith A, McKernan R, Metters K, O'Neill GP, Lacaille JC, Hebert TE: Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action. Mol Pharmacol. 2001 Jan;59(1):144-52. [PubMed:11125035]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
G-protein coupled gaba receptor activity
Specific Function
Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2. Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coup...
Gene Name
GABBR2
Uniprot ID
O75899
Uniprot Name
Gamma-aminobutyric acid type B receptor subunit 2
Molecular Weight
105820.52 Da
References
  1. Ng GY, Bertrand S, Sullivan R, Ethier N, Wang J, Yergey J, Belley M, Trimble L, Bateman K, Alder L, Smith A, McKernan R, Metters K, O'Neill GP, Lacaille JC, Hebert TE: Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action. Mol Pharmacol. 2001 Jan;59(1):144-52. [PubMed:11125035]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
L-valine transaminase activity
Specific Function
Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine.
Gene Name
BCAT1
Uniprot ID
P54687
Uniprot Name
Branched-chain-amino-acid aminotransferase, cytosolic
Molecular Weight
42965.815 Da
References
  1. Goto M, Miyahara I, Hirotsu K, Conway M, Yennawar N, Islam MM, Hutson SM: Structural determinants for branched-chain aminotransferase isozyme-specific inhibition by the anticonvulsant drug gabapentin. J Biol Chem. 2005 Nov 4;280(44):37246-56. Epub 2005 Sep 1. [PubMed:16141215]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49